AdAlta Limited (ASX:1AD)
Australia · Delayed Price · Currency is AUD 0.0040
+0.0005 (14.29%)
Aug 5, 2026, 3:44 PM AEST
AdAlta Market Cap
AdAlta has a market cap or net worth of 12.85 million as of August 5, 2026. Its market cap has increased by 361.77% in one year.
Market Cap
12.85M
Enterprise Value
11.27M
Revenue
608.07K
Ranking
n/a
PE Ratio
n/a
Stock Price
0.00
ChartMarket Cap Chart
Since August 22, 2016, AdAlta's market cap has decreased from 28.00M to 12.85M, a decrease of -54.11%. That is a compound annual growth rate of -7.52%.
| Date | Market Cap | % Change |
|---|---|---|
| Aug 5, 2026 | 12.85M | 86.60% |
| Dec 31, 2025 | 6.89M | -31.84% |
| Dec 30, 2024 | 10.10M | -19.94% |
| Dec 29, 2023 | 12.62M | -2.04% |
| Dec 29, 2022 | 12.88M | -45.79% |
| Dec 29, 2021 | 23.76M | -22.47% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
| Aug 22, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Patrys | 22.00M |
| Neurotech International | 21.08M |
| Argenica Therapeutics | 19.91M |
| Ceryvyn Therapeutics | 16.42M |
| ReNerve | 14.65M |
| Immuron | 11.76M |
| Cambium Bio | 11.21M |
| Bio-Gene Technology | 8.88M |